A Study of a Urine Test to Detect Colorectal Cancer

Part of paid clinical trials in New York, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07649057
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 3-metabolite biosensor — DIAGNOSTIC_TEST
    3-metabolite biosensor will identify participants with colorectal cancer (CRC) and precancerous polyps

Study Details

The purpose of this study is to find out whether a urine test can detect colorectal cancer (CRC) and precancerous polyps in participants living in Ghana, Tanzania, and South Africa.

Key Dates

Start date
Jun 11, 2026
Status verified
Jun 2026
Primary completion
Jun 11, 2028
Completion
Jun 11, 2028

Study Design

Enrollment
210 participants (estimated)

Arms

  • Arm: Participants with Colorectal Cancer/CRC
    Participants will either have symptoms of colorectal cancer/CRC, presented for a screening colonoscopy, or one of the following: pathologic diagnosis of CRC, colonoscopy demonstrating adenomatous polyps, or colonoscopy demonstrating no colon or premalignant or malignant pathology

Primary Outcome Measure

Sensitivity of 3-metabolite biosensor [ Time Frame: up to 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Peter Kingham, MD
212-639-5260

Find similar trials in New York, NY

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Memorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies